Publicaciones en las que colabora con Eva Bandrés Elizalde (16)

2020

  1. Assessment of minimal residual disease by next generation sequencing in peripheral blood as a complementary tool for personalized transplant monitoring in myeloid neoplasms

    Journal of Clinical Medicine, Vol. 9, Núm. 12, pp. 1-20

  2. Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression

    British Journal of Haematology, Vol. 189, Núm. 6, pp. 1064-1073

2010

  1. EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2

    British Journal of Cancer, Vol. 103, Núm. 8, pp. 1292-1296

  2. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

    Blood, Vol. 115, Núm. 3, pp. 615-625

2009

  1. Epigenetic regulation of MicroRNAs in acute lymphoblastic leukemia

    Journal of Clinical Oncology, Vol. 27, Núm. 8, pp. 1316-1322

  2. Epigenetic regulation of microRNA expression in colorectal cancer

    International Journal of Cancer, Vol. 125, Núm. 11, pp. 2737-2743

  3. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia

    Cancer Research, Vol. 69, Núm. 10, pp. 4443-4453

  4. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells

    Clinical Cancer Research, Vol. 15, Núm. 7, pp. 2281-2290

2008

  1. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth

    Molecular Cancer Research, Vol. 6, Núm. 12, pp. 1830-1840

2007

  1. Erratum: JAK2-V617F activating mutation in acute myeloid leukemia: Prognostic impact and association with other molecular markers (Leukemia (2007) vol. 21 (2386-2390) 10.1038/sj.leu.2404812)

    Leukemia

  2. JAK2-V617F activating mutation in acute myeloid leukemia: Prognostic impact and association with other molecular markers [15]

    Leukemia

  3. MicroRNAs as cancer players: Potential clinical and biological effects

    DNA and Cell Biology, Vol. 26, Núm. 5, pp. 273-282

2006

  1. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues

    Molecular Cancer, Vol. 5

2000

  1. The increase of IFN-γ production through aging correlates with the expanded CD8(+high)CD28-CD57+ subpopulation

    Clinical Immunology, Vol. 96, Núm. 3, pp. 230-235

1999

  1. Cytokine flow cytometry differentiates the clinical status of multiple sclerosis (MS) patients

    Clinical and Experimental Immunology, Vol. 115, Núm. 3, pp. 521-525

1998

  1. Cinética de la modulación por citoquinas de FcR en monocitos de pacientes con lupus eritematoso sistémico (LES)

    Anales del sistema sanitario de Navarra, Vol. 21, Núm. 3, pp. 57-62